<div id="readability-page-1"><p>Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has earned an average rating of &#34;Moderate Buy&#34; from the eight analysts that are currently  covering the stock, Marketbeat.com reports. One equities research analyst  has rated the stock with a sell recommendation, one  has given a hold recommendation and six have issued  a buy recommendation on  the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $26.25.</p><p>BNTC has been the topic of several recent analyst reports. Citizens Jmp increased their price target on Benitec Biopharma from $20.00 to $22.00 and gave the stock a &#34;market outperform&#34; rating in a report on Tuesday, November 4th. Oppenheimer  restated an &#34;outperform&#34; rating and set a $29.00 target price (down previously from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. Wall Street Zen upgraded Benitec Biopharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 22nd. HC Wainwright  set a $32.00 price target on shares of Benitec Biopharma and gave the company a &#34;buy&#34; rating in a research report on Monday, November 24th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Benitec Biopharma in a research report on Wednesday, October 8th.</p><div><p><span></span><span>Get <strong>Benitec Biopharma</strong> alerts:</span></p></div><p><b>Read Our Latest Stock Report on BNTC</b></p><h2>Insider Buying and Selling at Benitec Biopharma</h2><p>In related news, Director Suvretta Capital Management, L acquired 1,481,481 shares of the business's stock in a transaction dated Friday, November 7th. The shares were purchased at an average price of $13.50 per share, for a total transaction of $19,999,993.50. Following the completion of the acquisition, the director directly owned 9,538,175 shares in the company, valued at $128,765,362.50. The trade was a 18.39% increase in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own  4.80% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. raised its position in  Benitec Biopharma by 40.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 154,414 shares of the biotechnology company's stock worth $2,166,000 after buying an additional 44,489 shares during the last quarter.  UBS Group AG raised its position in shares of  Benitec Biopharma by 458.8% during the 3rd quarter. UBS Group AG now owns 99,941 shares of the biotechnology company's stock worth $1,402,000 after purchasing an additional 82,057 shares during the last quarter.  BNP Paribas Financial Markets lifted its stake in  Benitec Biopharma by 44.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company's stock valued at $41,000 after buying an additional 904 shares in the last quarter.  Russell Investments Group Ltd. acquired a new stake in  Benitec Biopharma in the 3rd quarter worth about $79,000.  Finally, Vanguard Group Inc. increased its stake in  Benitec Biopharma by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company's stock worth $13,919,000 after buying an additional 22,948 shares in the last quarter. 52.19% of the stock is owned by institutional investors and hedge funds. </p><h2>Benitec Biopharma Price Performance</h2><p>Shares of BNTC opened at $11.98 on Monday. Benitec Biopharma has a 1 year low of $9.70 and a 1 year high of $17.15. The business's 50 day simple moving average is $14.11 and its 200-day simple moving average is $13.62. The stock has a market capitalization of $405.64 million, a price-to-earnings ratio of -9.90 and a beta of 0.20. </p><p>Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.13.  On average, sell-side analysts expect that  Benitec Biopharma will post -1.48 earnings per share for the current year. </p><h2>About Benitec Biopharma</h2> (Get Free Report)<p>Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Benitec Biopharma</li><li>Trading Stocks: RSI and Why it's Useful</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>What Does a Stock Split Mean? </li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk5UQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk5UQw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Benitec Biopharma Right Now?</h2><p>Before you consider Benitec Biopharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.</p><p>While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BNTC

<p>Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat.com reports.</p>

Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of "Moderate Buy" by Brokerages